BiPhasix can entrap & transport drugs & biologics products through human skin to achieve therapeutic benefit in a wide range of indications and can carry active pharmaceutical ingredients in the range of ~300 Da to ~100 kDa
Pivot’s Proprietary BiPhasix can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal and rectal.
BiPhasix can be formulated to effect varying degrees of tissue penetration and rate of release at the target site, in accordance with a desired clinical goal.
Studies have shown that BiPhasix can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes.
BiPhasix has demonstrated excellent stability with most therapeutic agents tested, and in particular, proteins - which are characteristically unstable in traditional vehicles. Vulnerable drugs can be shielded from degradation in BiPhasix, thereby enhancing their clinical usefulness and commercial viability. Compatible with most plastics and other container-closure systems
Solvent Free No Animal Products
Formulated with biocompatible materials. Neither organic solvents nor ingredients of animal origin are used in their manufacture.
Clinical supplies and commercial batches can be prepared using conventional manufacturing equipment and container closure systems. Specialized equipment and extensive capital investment are not required.
Provides market exclusivity for new drugs and the ability to introduce patented line extensions to a product portfolio